The goal of this study is to compare the effectiveness and safety of two hemoglobin F inducer. This is single centered interventional pilot study is to compare the efficacy and safety parameters in beta thalassemia patients. As this is a pilot study, the investigator took a small number of patients. The Sample size was calculated by the World health organization sample size calculator. After screening 39 patients and 24 patients were eligible for enrollment in this study. The main objective was to evaluate safety of both drugs in genetic disorder like thalassemia. for safety evaluation, hematological parameters were evaluated that includes total bilirubin , indirect bilirubin, Serum Glutamate Pyruvate Transaminase, serum glutamic-oxaloacetic transaminase, urea, creatinine and lactate dehydrogenase were monitored . Moreover to evaluate the efficacy of drug, hematological parameters that includes hemoglobin, red blood cells , nucleated red blood cells , reticulocytes count, Red blood cells indices ( mean corpuscular hemoglobin, mean corpuscular volume and mean corpuscular hemoglobin concentration) , white blood cells and platelets were done. Another important parameters to evaluate the efficacy of hemoglobin F inducer is transfusion frequency. Test were done at baseline and after completion of study means after 06 months.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
24
Thalidomide is available in capsulated form in the strength of 100 mg and 50 mg. It was given according to the weight of the patient. Due to somnolence, it was advised to give at night only.
Hydroxyurea is available in capsulated form under the brand of hydrea. Its available strength is 500 mg . Dosing depends upon weight of patient, that is 15mg/kg/day. so patients unable to take full capsule due to low weight, was advised to take hydroxyurea syrup.
National Institute of Blood Diseases and Bone Marrow Transplantation
Karachi, Sindh, Pakistan
comparison of hemoglobin
Hemoglobin
Time frame: 06 months
comparison of red blood cells
Red blood cells
Time frame: 06 months
comparison of Mean corpuscular volume
Mean corpuscular volume
Time frame: 06 months
comparison of Mean Corpuscular Hemoglobin
Mean Corpuscular Hemoglobin
Time frame: 06 months
comparison of Mean Corpuscular Hemoglobin concentration
Mean Corpuscular Hemoglobin concentration
Time frame: 06 months
comparison of Indirect bilirubin
Indirect bilirubin
Time frame: 06 months
comparison of Total Bilirubin
Total Bilirubin
Time frame: 06 months
comparison of Serum glutamic pyruvic transaminase
Serum glutamic pyruvic transaminase
Time frame: 06 months
comparison of glutamic-oxaloacetic transaminase
glutamic-oxaloacetic transaminase
Time frame: 06 months
comparison of white blood cells
white blood cells
Time frame: 06 months
comparison of platelets
Platelets
Time frame: 06 months
comparison of urea
Urea
Time frame: 06 months
comparison of creatinine
Creatinine
Time frame: 06 months
comparison of Lactate dehydrogenase baseline and after the completion of study.
Lactate dehydrogenase
Time frame: 06 months
comparison of tranfusion frequency baseline and after the completion of study.
Transfusion interval
Time frame: 06 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.